Ratings by Lucid Capital Markets (Dev Prasad)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 9/8/2026 | Adlai Nortye Ltd. | ANL | New Coverage | Buy (N/A) |
15.01 (15.09) |
0.53% | Details | |
| 8/20/2026 | Eloxx Pharma | ELOX | New Coverage | Buy (N/A) |
18.16 (16.28) |
-10.35% | Details | |
| 7/27/2026 | Polaryx Therapeutics | PLYX | New Coverage | Buy (N/A) |
2.05 (1.99) |
-2.93% | Details | |
| 5/4/2026 | Quoin Pharmaceuticals | QNRX | New Coverage | Buy (N/A) |
6.21 (6.90) |
11.11% | Details | |
| 2/24/2026 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 12/15/2025 | Palvella Therapeutics | PVLA | Maintain | Buy (N/A) |
|
Details | ||
| 12/3/2025 | Palatin Technologies | PTN | New Coverage | Buy (N/A) |
19.63 (12.02) |
-38.77% | Details | |
| 11/5/2025 | Verrica Pharmaceuticals | VRCA | New Coverage | Buy (N/A) |
3.28 (4.95) |
50.91% | Details | |
| 9/15/2025 | aTyr Pharma | ATYR | Downgrade | Neutral (Buy) |
6.03 (0.43) |
-92.87% | Details | |
| 8/25/2025 | Cue Biopharma | CUE | New Coverage | Buy (N/A) |
0.83 (28.00) |
3273.49% | Details | |
| 6/17/2025 | Opus Genetics | IRD | New Coverage | Buy (N/A) |
0.94 (6.07) |
545.74% | Details | |
| 5/23/2025 | Edesa Biotech Inc. | EDSA | New Coverage | Buy (N/A) |
2.01 (4.66) |
131.84% | Details | |
| 3/18/2025 | Palvella Therapeutics | PVLA | New Coverage | Buy (N/A) |
27.50 (150.39) |
446.87% | Details | |
| 12/17/2024 | Avalo Therapeutics Inc. | AVTX | New Coverage | Buy (N/A) |
9.42 (17.18) |
82.38% | Details | |
| 12/17/2024 | iBio, Inc. | IBIO | New Coverage | Buy (N/A) |
2.35 (1.23) |
-47.66% | Details | |
| 12/17/2024 | CalciMedica | CALC | New Coverage | Buy (N/A) |
2.81 (2.12) |
-24.56% | Details | |
| 11/19/2024 | Inflarx NV | IFRX | New Coverage | Buy (N/A) |
1.74 (2.05) |
17.82% | Details | |
| 11/19/2024 | aTyr Pharma | ATYR | New Coverage | Buy (N/A) |
3.01 (6.03) |
100.33% | Details |
